BioCryst Pharmaceuticals, Inc.
Durham
NC
27703
United States
567 articles about BioCryst Pharmaceuticals, Inc.
-
BioCryst to Present at Upcoming Investor Conferences in March 2022
3/3/2022
BioCryst Pharmaceuticals, Inc. announced that the company will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022, at 9:50 a.m. ET.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 02, 2022
3/2/2022
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 17 newly-hired employees stock options to purchase an aggregate of 228,000 shares, and restricted stock units covering an aggregate of 62,000 shares, of BioCryst common stock.
-
BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)
2/24/2022
BioCryst Pharmaceuticals, Inc. announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema showing sustained reductions in attack rates and improvement in quality of life among patients living with HAE, regardless of their baseline attack rates and initial responses to ORLADEYO.
-
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
2/23/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases
2/22/2022
BioCryst Pharmaceuticals, Inc. today announced the enrollment of the first patient in the RENEW proof-of-concept basket study with its oral Factor D inhibitor, BCX9930, in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).
-
BioSpace Movers & Shakers, Feb. 11
2/11/2022
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
BioCryst to Report Fourth Quarter 2021 Financial Results on February 23
2/9/2022
BioCryst Pharmaceuticals, Inc. announced that the company will report its fourth quarter and full year 2021 financial results Wednesday, February 23, 2022.
-
BioCryst Appoints Machelle Sanders to Board of Directors
2/8/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed North Carolina Secretary of Commerce, and accomplished pharmaceutical operations executive, Machelle Sanders, to its board of directors.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 03, 2022
2/3/2022
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 31 newly-hired employees stock options to purchase an aggregate of 213,500 shares, and restricted stock units covering an aggregate of 24,700 shares, of BioCryst common stock.
-
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting
2/1/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present three abstracts featuring new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.
-
When presented with ORLADEYO, both patients and physicians recognized immediately the freedom gained with the once-daily prophylactic therapy and indicated a high willingness to use.
-
BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance
1/10/2022
BioCryst Pharmaceuticals, Inc. announced preliminary, unaudited ORLADEYO® revenue for the fourth quarter and full year 2021 and provided new guidance for full year 2022 ORLADEYO net revenue and expected peak ORLADEYO sales.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
1/7/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-1 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH).
-
BioCryst to Present at 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
BioCryst Pharmaceuticals, Inc. today announced that the company will present at the 40th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Monday, January 10, 2022 at 9:45 a.m. ET.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 04, 2022
1/4/2022
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired employees inducement options to purchase an aggregate of 91,000 shares of BioCryst common stock on December 31, 2021 as inducements material to each employee entering into employment with BioCryst.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
BioCryst Reported Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3/2021
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired employees inducement options to purchase an aggregate of 84,000 shares of BioCryst common stock on November 30, 2021 as inducements material to each employee entering into employment with BioCryst.
-
BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
11/29/2021
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-2 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH).
-
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
11/22/2021
BioCryst Pharmaceuticals, Inc., Royalty Pharma plc and OMERS Capital Markets, announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing.